A bdominal aortic aneurysm (AAA) is a common degenerative condition associated with complex interactions between genetic and environmental factors in the elderly and is considered to be a potent life-threatening disorder.
A bdominal aortic aneurysm (AAA) is a common degenerative condition associated with complex interactions between genetic and environmental factors in the elderly and is considered to be a potent life-threatening disorder. 1 The high mortality of AAA is mainly because of the aneurysm rupture, and the risk of rupture is correlated with the size of AAA. Therefore, maximal diameter of AAA is commonly used to predict high-risk patients for aneurysm rupture in the clinical setting. In general, patients with a large AAA undergo elective surgical or endovascular repair, and these procedures achieve a favorable outcome. However, many asymptomatic patients with a small AAA are diagnosed incidentally by ultrasonography or computed tomography during routine abdominal screening. 2 These patients only receive continued monitoring by noninvasive imaging methods, because there is no effective treatment option for small AAA despite their gradual expansion. 1, 3 Therefore, the development of a novel therapeutic approach, especially pharmacological therapy, to regress AAA or prevent aneurysm progression is awaited.
The main pathophysiology of AAA is chronic inflammation in the aortic wall, and the role of the renin-angiotensin system (RAS) in AAA has received considerable attention, because angiotensin II, the main effector peptide in RAS, is considered to be a key factor to induce inflammation in the arterial wall. 4, 5 In addition, recent studies have indicated the importance of tissue RAS in the vasculature. RAS components can be detected in the human aneurysm wall and in atherosclerotic lesions, and its activation is thought to participate in disease progression. 6 Indeed, we and others have previously reported the inhibitory effects of angiotensin II receptor blockers and angiotensin-converting enzyme inhibitors on experimental AAA formation independent of their blood pressure (BP)-lowering effect. 1, 7 However, despite showing positive results in experimental studies, there is no evidence for a beneficial effect of RAS inhibitors on AAA progression in clinical trials. 8 Thus, we suggested that inhibition of multiple steps of RAS might be required to treat AAA because there are many compensatory mechanisms to induce effector peptides in RAS. Indeed, angiotensin II is known to be produced by a non-angiotensin-converting enzyme, chymase, in human atherosclerotic lesions and the aneurysm wall. 6, 9 Therefore, Abstract-Angiotensin II is thought to participate in aneurysm formation, because of its ability to induce and perpetuate inflammation in the aortic wall. Because activation of renin is the first step of the renin-angiotensin system, renin inhibition could inhibit all components of this system effectively. Therefore, we examined the hypothesis that direct inhibition of renin activity could decrease the expansion of aortic aneurysm using a rabbit model. Aortic dilatation was induced by incubation with elastase around the rabbit abdominal aorta. Continuous administration of a direct renin inhibitor, aliskiren, was started at 1 week before incubation with elastase and continued for 5 weeks. Treatment with aliskiren markedly inhibited tissue renin activation and resulted in a significant reduction in angiotensin I and II production in the aneurysm wall. Consequently, the inhibition of renin activity prevented the expansion of experimental aortic aneurysm associated with preservation of the medial layer, independent of its blood pressure-lowering effect. Administration of aliskiren led to the inhibition of activation of NF-κB (nuclear factor-κB), AP-1 (activator protein-1), and CREB (cAMP response element-binding protein), which are thought to cooperatively regulate the inflammatory gene expression profile associated with aneurysm formation. As a result, treatment with aliskiren inhibited macrophage accumulation through suppression of MCP-1 (monocyte chemoattractant protein-1) and CCL4 (C-C motif chemokine ligand 4) expression, and TNF-α (tumor necrosis factor-α) production and activation of MMP-2 (matrix metalloproteinase-2) and MMP-9 (matrix metalloproteinase-9) were also suppressed in the aneurysm wall. In addition, inhibition of (pro)renin receptor elevation was also observed after treatment with aliskiren. Direct inhibition of renin activity using aliskiren prevented the progression of aortic aneurysm, suggesting it as a therapeutic option to treat abdominal aortic aneurysm. (Hypertension.
we hypothesized that direct blockade of renin activity, the first step of RAS, could effectively inhibit all RAS components including chymase-induced angiotensin II formation, leading to a potent therapeutic effect on aneurysm progression. Among several RAS inhibitors, a direct renin inhibitor, aliskiren, is also available as an antihypertensive drug, and its pleiotropic effects have been observed in several disease conditions, such as atherosclerosis and diabetic nephropathy. 10 In this study, we investigated the effects of direct renin inhibition by aliskiren on aneurysm progression using an elastaseinduced rabbit AAA model.
Methods
Additional details are provided in the online-only Data Supplement.
Procedure of AAA Model and Inhibition of Renin Activity
We used an elastase-induced rabbit AAA model to investigate the effect of direct renin inhibition on aneurysm formation, as previously described.
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BP and heart rate were measured from the left forelimb using a noninvasive oscillometric method in conscious rabbits. 12, 13 To inhibit renin activity, rabbits received a continuous infusion of a direct renin inhibitor, aliskiren (Novartis Pharmaceuticals), via osmotic mini-pumps (Alzet model 2ML2) for a period of 1 week before elastase incubation until the time of aneurysm harvest (1 or 4 weeks after incubation). One or 4 mini-pumps were implanted into the subcutaneous layer of the neck of rabbits on days 0, 7, and 21 for administration of a low dose (10 mg/kg per day) or high dose (50 mg/kg per day) of aliskiren, respectively. Animals were divided into 4 groups: sham (without incubation with elastase, n=9), vehicle control (treatment with saline, n=13), treatment with low dose of aliskiren (n=14), and treatment with high dose of aliskiren (n=9). Five animals in the sham, vehicle control, and low-dose aliskiren groups were euthanized at 1 week after operation to investigate the molecular mechanisms of treatment with aliskiren. The other animals were euthanized at 4 weeks after incubation with elastase to examine the effect of aliskiren on aortic expansion.
Ultrasonography
Ultrasonography was used to assess dilatation of the abdominal aorta. A cardiovascular ultrasound system (Power Vision 6000; Toshiba, Tokyo, Japan) and a linear transducer (15 MHz) were used to image the abdominal aorta noninvasively in anesthetized rabbits. The aortic size was measured before and after operation, once a week up to 4 weeks.
Histological and Immunohistochemical Studies
Animals were euthanized at 4 weeks after elastase incubation. The aorta was carefully dissected and processed for routine paraffin embedding. Aortic tissue cross sections (6 µm) were stained with both hematoxylin and eosin and Elastic van Gieson stain in a standard manner. To evaluate residual mature elastin, the area of elastic fibers in Elastic van Gieson-stained sections was calculated by quantitative morphometric analysis with a computerized sketching program (n=5 per group).
Immunohistochemical staining was performed using the immunoperoxidase avidin-biotin complex method, according to the manufacturer's specifications (Vectastain Elite ABC kit). Diluted primary antibodies against rabbit macrophages (RAM 11; 1:100; Dako) were applied to frozen cross sections (5 µm) of AAA tissues at 1 week after operation (n=5 per group).
Renin Activity Assay and Enzyme Immunoassay for Angiotensin I and II
The aneurysm wall was homogenized and total protein extracted at 1 week after incubation with elastase. Protein extracts (20 µg) were assayed for renin activity using a fluorimetric SensoLyte 520 Renin Assay Kit (Anaspec, CA) following the manufacturer's instructions (n=5 per group). Fluorescence was detected using a luminometer, and the data showed relative fluorescent units per minute. Protein extracts (100 µg) were also assayed for angiotensin I and II concentrations using enzyme immunoassay kits (n=5 per group; Peninsula Laboratories International, Inc).
SDS-PAGE Zymography
Activation of MMP (matrix metalloproteinase) in the rabbit aneurysm wall was assessed in each group at 1 week after operation (n=4 per group). MMP activities were measured in protein extracts (20 µg) by SDS-PAGE zymography as previously described.
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Western Blotting
Western blotting was performed to analyze the expression of components of RAS in the aneurysm wall at 1 week after incubation with elastase (n=5 per group).
Electrophoretic Mobility Shift Assay
Nuclear extracts were prepared from the entire aneurysm wall including adventitia with a CelLytic NuCLEAR Extraction Kit (SigmaAldrich). Then, electrophoretic mobility shift assay was performed to analyze the activation of transcription factors in nuclear extracts with a gel shift assay system (n=5 per group; Promega Corp), according to the manufacturer's specifications.
Real-Time RT-PCR
At 1 week after operation, total RNA was extracted from the rabbit aneurysm wall with an RNeasy Fibrous Tissue Mini Kit (n=5 per group; Qiagen, MD). Real-time RT-PCR (reverse transcription-polymerase chain reaction) was performed using a Power SYBR Green RNA-to-CT 1-step Kit (Applied Biosystems). Primers based on the published sequences for rabbit TNF-α (tumor necrosis factor-α), CCL4 (C-C motif chemokine ligand 4), and GAPDH were used.
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Statistical Analysis
Statistical analysis was performed using JMP software package version 9.0 (SAS Institute, Inc). Continuous variables with normal distribution were expressed as mean±SEM, and 1-way ANOVA followed by Tukey-Kramer multiple range test was used for comparisons among multiple groups. Changes in aortic size, BP, and heart rate were analyzed by multiway repeated-measures ANOVA and Tukey-Kramer multiple range test. P<0.05 was considered significant.
Results
Effects of Direct Renin Inhibition on Hemodynamics and Aneurysm Formation
We examined the effects of direct renin inhibition by aliskiren on aneurysm formation in an elastase-induced rabbit AAA model. Aliskiren was administered at 2 doses, 10 mg/kg per day (low dose) and 50 mg/kg per day (high dose). Systemic administration of the low dose of aliskiren did not alter hemodynamic measures including BP and heart rate. However, there was a sustained decrease in BP after infusion of the high dose of aliskiren, whereas heart rate was not changed ( Figure 1A ). There was no significant difference in body weight between rabbits treated with saline and aliskiren during the experimental period (data not shown).
Aortic diameter markedly increased in rabbits treated with both saline (vehicle control) and aliskiren at 1 week after incubation with elastase, as assessed by ultrasonography ( Figure 1B) . Although a continuous increase in aortic diameter was observed in the vehicle control group, treatment with aliskiren significantly inhibited aortic dilatation from 2 weeks after incubation with elastase. Interestingly, there was no significant difference in aortic dilatation between the high dose and low dose of aliskiren ( Figure 1C ; Figure S1 in the online-only Data Supplement). In the histological analysis, Elastic van Gieson staining demonstrated that treatment with aliskiren preserved elastic fibers in the medial layer, whereas treatment with saline (vehicle control) was associated with marked destruction of elastic fibers at 4 weeks after incubation with elastase ( Figure 2 ).
Inhibition of RAS in AAA Tissue by Direct Renin Inhibition
Because administration of the high dose of aliskiren did not show further inhibitory effects on aneurysm formation compared with the low dose, we investigated the molecular mechanisms of direct renin inhibition using samples from rabbits treated with the low dose of aliskiren. In addition, in rabbits treated with the low dose of aliskiren, the effect of BP lowering on aneurysm development could be avoided.
First, we investigated the effect of aliskiren on tissue RAS activity. Although systemic RAS was not activated, tissue angiotensin I and II levels were markedly increased in rabbits in the vehicle control group, and the production of these peptides was significantly inhibited by treatment with aliskiren ( Figure 3A ; Figure S2 ). In contrast, Western blotting demonstrated that the concentrations of renin and prorenin ((pro) renin) in the aneurysm wall were increased in animals treated with both saline and aliskiren ( Figure 3B ). However, administration of aliskiren almost completely inhibited the upregulation of tissue renin activity ( Figure 3C) .
Next, the expression of receptors associated with RAS was also investigated. Western blotting demonstrated that expression of the AT1R (angiotensin II type I receptor) in the aortic wall was not increased in both the saline-and aliskiren-treated groups compared with the sham-operated group ( Figure 3D) . However, expression of the (pro)renin receptor, ATP6AP2 (ATPase H(+)-transporting lysosomal accessory protein 2), was significantly increased in the aneurysm wall after incubation with elastase in the vehicle control group. Interestingly, treatment with aliskiren significantly suppressed this upregulation ( Figure 3D ). These findings indicate that AAA progression was associated with an increase in tissue RAS activation, and inhibition of renin activity by aliskiren resulted in inhibition of angiotensin II production and (pro)renin receptor elevation in the aneurysm wall.
Inhibition of Inflammatory Response by Direct Renin Inhibition
We investigated the effects of direct renin inhibition on transcriptional activity because angiotensin II is known to activate several transcription factors inducing an inflammatory response. Electrophoretic mobility shift assay study demonstrated that NF-κB (nuclear factor-κB), AP-1 (activator protein-1), and CREB (cAMP response element-binding protein) were increased in the elastase-induced aneurysm wall. However, administration of aliskiren significantly attenuated their activation (Figure 4 ). Aneurysm formation is closely related to chronic inflammation, and these transcription factors are well known to regulate a set of genes associated with inflammatory and immune responses. Therefore, we evaluated the changes in expression of inflammatory mediators associated with AAA formation. Treatment with aliskiren significantly inhibited chemokine expression such as MCP-1 (monocyte chemoattractant protein-1) and CCL4 ( Figure 5A and 5B). As a result, although many macrophages migrated into the adventitia and media of the aorta treated with saline, the recruitment of macrophages was significantly suppressed by treatment with aliskiren ( Figure 5C ). Although migrating macrophages can secrete numerous proinflammatory cytokines in the aneurysm wall, a significant reduction in TNF-α gene expression by treatment with aliskiren was observed ( Figure 6A ). Moreover, destruction of the aortic wall is mainly because of activation of several proteases, especially MMP-2 and MMP-9. Therefore, activation of MMP in the aneurysm wall was measured by gelatin zymography. Treatment with aliskiren significantly reduced the production of MMP-2 and MMP-9 and transformation into the active form of MMP-2 compared with vehicle control ( Figure 6B ).
Discussion
Here, we demonstrated that direct inhibition of renin by aliskiren significantly inhibited the progression of AAA, independent of its BP-lowering effect, in a rabbit AAA model. Direct renin inhibition attenuated tissue RAS activation and could lead to suppression of transcriptional activity of NF-κB, AP-1, and CREB, resulting in significant inhibition of inflammatory response and (pro)renin receptor elevation in the aneurysm wall.
Emerging evidence indicates a pivotal role of RAS in the initiation and progression of AAA, associated with enhanced expression of a wide variety of proinflammatory cytokines, chemokines, and proteases. In addition, recent studies demonstrated that mineralocorticoid receptor activation by aldosterone plays an important role in the pathogenesis of AAA. Angiotensin II is a potent stimulator of aldosterone synthesis, and activation of mineralocorticoid receptor mediates extracellular matrix remodeling and inflammatory response in several disease conditions including AAA formation. 16, 17 Although RAS involves various steps to produce effector peptides, it is activated by cleavage of angiotensinogen to angiotensin I by renin. 4 Therefore, the rate-limiting step of RAS is under the control of renin activity. In the present study, the levels of tissue renin activity and other components of RAS in the aortic wall were significantly increased in vehicle control rabbits after incubation with elastase, and the aortic diameter gradually expanded during the experimental period. In contrast, treatment with aliskiren inhibited the activation of tissue RAS including angiotensin I and II production in the aneurysm wall via a marked reduction in renin activity and significantly inhibited sustained aortic dilatation. Although elastase can induce direct disruption of extracellular matrix in the human aortic wall, 18, 19 RAS is thought to contribute to the prolonged disruption of the aortic wall in this AAA model. Interestingly, the efficacy of high-dose aliskiren on AAA development was similar to that of low-dose aliskiren. The low dose of aliskiren almost completely inhibited tissue renin activity. In addition, because the effects of direct renin inhibition were investigated in a normotensive AAA model, the BP-lowering effect of the high dose of aliskiren could not affect AAA progression. Moreover, several clinical studies demonstrated that hypertension was not associated with AAA expansion rate. 20, 21 Therefore, a high dose of aliskiren might not obtain a further therapeutic effect on AAA progression.
In the present study, the therapeutic effects of a low dose of aliskiren were sufficient to prevent AAA progression and were not associated with its ability to lower the BP. A similar observation was previously reported in an angiotensin II-induced mouse AAA model. 22 However, in contrast to our study, this mouse model required administration of a high dose of angiotensin II, and an increase in BP participated in AAA formation. Therefore, the pathophysiology of AAA formation and the molecular mechanisms underlying prevention of AAA would be different from those in our study in many ways. However, the results strongly support the feasibility of aliskiren to treat human AAA.
Although there is no direct evidence, the (pro)renin receptor might contribute to AAA progression, in addition to the classical RAS. The MAPK (mitogen-activated protein kinase) pathway is thought to contribute to AAA formation, and it has been reported that binding of (pro)renin to its receptor directly stimulates this cascade, independently of the angiotensin II/AT1R signal. 23, 24 Interestingly, although the expression of vascular (pro)renin receptors was increased in vehicle control rabbits after incubation with elastase, treatment with aliskiren inhibited the upregulation of (pro)renin receptors in the aneurysm wall. A previous in vitro study also reported that expression of the (pro)renin receptor was decreased by aliskiren in cultured vascular smooth muscle cells. 25 On the contrary, angiotensin II is well known to induce activation of several transcription factors, and cross talk among activated transcription factors mediates gain or loss of function in the fine-tuning of transcriptional regulation. In the present study, activation of NF-κB, AP-1, and CREB was observed in the aneurysm wall, and direct renin inhibition suppressed their activation. Several previous studies demonstrated that inflammatory cells were recruited in the aneurysm wall in response to the acute elastase injury and participated in the progressive enlargement of AAA. 26, 27 This inflammatory response is thought to lead to tissue RAS activation, resulting in activation of NF-κB, AP-1, and CREB. It has been reported that angiotensin II activated NF-κB, AP-1, and CREB in in vitro studies. [28] [29] [30] [31] [32] Angiotensin II mediates NF-κB activation through the phosphorylation and degradation of IκB (inhibitor of nuclear factor-κB), 28, 29 and AT1R or (pro)renin receptor-induced MAPK signaling leads to activation of AP-1 and CREB as downstream transcription factors. [30] [31] [32] Importantly, the presence of binding sites for NF-κB, AP-1, and CREB was confirmed in the promoter region of the (pro)renin receptor, and activation of these transcription factors accelerated (pro) renin receptor expression in neurons and mesangial cells. 30, 33 Therefore, it is suggested that administration of aliskiren might attenuate (pro)renin receptor elevation through inhibition of activation of these transcription factors.
NF-κB and AP-1 are well known to regulate transcription of a set of genes associated with immune and inflammatory responses and play a critical role in AAA pathogenesis. We have previously reported that inhibition of NF-κB activity regressed AAA formation in an already-formed rabbit AAA model. 11 Also, the inhibition of JNK (c-Jun-NH2-terminal kinase)/AP-1 pathway mediated the regression of AAA in an angiotensin II-induced mouse AAA model. 34 In contrast, previous studies demonstrated that activated CREB inhibited activation of NF-κB through blockade of binding of coactivators. 35 However, recent studies also reported the participation of CREB in accelerated inflammatory process. 32 In addition, it has been reported that angiotensin II-induced CREB activation resulted in activation of IL-6 (interleukin-6) gene transcription in rat vascular smooth muscle cells. 36 Therefore, although a precise role of CREB in AAA formation is not clear, these transcription factors are thought to act in concert to regulate inflammatory response. Among many proinflammatory mediators, TNF-α is an important cytokine in several disease progressions including AAA. In clinical studies, TNF-α was expressed in the human AAA wall. In addition, serum TNF-α levels were elevated in patients with AAA and were significantly higher in patients with small AAA than large AAA. 37, 38 Although angiotensin II can increase TNF-α expression, transactivation of TNF-α is regulated by NF-κB, AP-1, and CREB. 29, 32 In contrast, TNF-α also activates these transcription factors. 39, 40 These interactions among TNF-α and these transcription factors might lead to a positive feedback loop, resulting in prolonged inflammatory response in the aortic wall. Because administration of aliskiren inhibited gene expression of TNF-α because of suppression of activation of these transcription factors, aliskiren could block this vicious cycle and ameliorate abnormal gene expression associated with chronic inflammation in the aortic wall.
Recruitment of macrophages is one of the main findings in the human aneurysm wall, and migrating macrophages are a major source of several proinflammatory mediators. Interestingly, treatment with aliskiren could modulate function of migrating macrophages, because activated macrophages express all components of RAS. 41 MMP-2 and MMP-9 secreted from macrophages are predominant proteases in the process of destruction of the aortic wall. 42, 43 Expression of these MMP genes is primarily regulated at the transcriptional level, and NF-κB-and AP-1-binding sites have been found in both the MMP-2 and MMP-9 promoters. 44 Therefore, expression of these MMP genes would be inhibited by aliskiren through suppression of NF-κB and AP-1 activity. In addition, treatment with aliskiren inhibited accumulation of macrophages in the aneurysm wall via suppression of MCP-1 and CCL4 expression. Transcription of these chemokines is also regulated by NF-κB. In addition, we have previously reported that inhibition of NF-κB activation induced macrophage apoptosis. 11 Similarly, activation of CREB is also essential for macrophage survival. 45 For these reasons, the specificity of the therapeutic effects of renin inhibition might be associated with direct inhibition of proinflammatory gene expression driven by NF-κB, AP-1, and CREB and indirectly suppressed secretion of inflammatory mediators by decreasing the accumulation of macrophages. 
Perspectives
Direct renin inhibition by aliskiren significantly reduced excess RAS activation in the aneurysm wall. In addition, significant inhibition of activation of NF-κB, AP-1, and CREB was also observed after treatment with aliskiren. These transcription factors are thought to cooperatively regulate the inflammatory gene expression profile associated with AAA progression. Therefore, treatment with aliskiren inhibited AAA progression through anti-inflammatory effects, even in the absence of a BP-lowering effect. Direct inhibition of renin activity using aliskiren could become a potent therapeutic option for treating patients with small AAA.
